Ranbaxy-Teva Atorvastatin Mystery Deal Decoded: Many Likely Scenarios Aimed At “On Time” Launch
This article was originally published in PharmAsia News
Executive Summary
Industry sources tell PharmAsia News that Ranbaxy forged the Teva Lipitor deal as a back-up plan, one that could prove costly for Ranbaxy.
You may also be interested in...
Ranbaxy Chairman Says No Change To Lipitor Generic Launch Timeline In U.S.; Dismisses Speculation Of $1 Bn FDA Penalty
MUMBAI - Share prices of Ranbaxy Laboratories Ltd. rose nearly 5% on an otherwise flat day of trading at the Bombay Stock Exchange backed by news that the company is "on schedule" to launch generic versions of Lipitor (atorvastatin) in the United States
Ranbaxy Talks Up Monetization Of First To Files Like Lipitor, Diovan, Actos if FDA Issues Stay Foggy; Are Big Launches Imperilled?
MUMBAI - With no clarity emerging whatsoever on how Ranbaxy Laboratories Ltd. will resolve its five-year long dispute with U.S. FDA - which has led to a blanket ban on drugs manufactured at one of Ranbaxy's largest India-based sites - analysts now speculate that the company will most likely "explore monetizing" its key first-to-file opportunities in the U.S. like Lipitor (atorvastatin), Diovan (valsartan), Nexium (esomeprazole) and Actos (pioglitazone)
Ranbaxy Loses Tamsulosin Launch Opportunity To Impax; Analysts Raise Doubts About Nexium, Lipitor
MUMBAI - It's been a tricky and awkward situation for Ranbaxy since it admitted at the last minute to losing a big opportunity of launching the first generic version of prostate enlargement drug Flomax (tamsulosin) in the United States. On March 2, Impax launched the generic variant of the nearly $2 billion blockbuster drug as part of an October 2009 patent settlement inked with Boehringer Ingelheim